ADiTx Therapeutics, Inc. Appoints Joachim-Friedrich Kapp, as Vice President of Clinical Development, Autoimmunity
August 14, 2020 at 01:00 pm
Share
ADiTx Therapeutics, Inc. announced that it has appointed Dr. Joachim-Friedrich Kapp, MD, PhD as Vice President of Clinical Development, Autoimmunity, effective immediately. In his newly created role as Vice President of Clinical Development, Autoimmunity, Dr. Kapp will be responsible for all preparation, execution, regulatory and budgetary matters relating to Aditxt’s planned 2021 Phase I/IIA clinical trials. Dr. Kapp brings over 3 decades of experience working with global healthcare corporations and regulatory agencies such as the FDA and EMA. Notably, he is the former President of the Global Business Unit, (GBU) Specialized Therapeutics and member of the Executive Committee at Schering AG.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.